Conference Coverage

Lenalidomide branches out to lymphoma therapy

Publish date: January 25, 2013

 

AT THE ANNUAL MEETING OF THE AMERICAN SOCIETY OF HEMATOLOGY

Both Dr. Chiappella’s and Dr. Goy’s studies were supported in part by Celgene, maker of lenalidomide. Dr. Chiappella reported having no relevant disclosures. Dr. Goy is on Celgene’s speakers bureau.

Pages

Recommended Reading

2-D Echo Is Inadequate Cardiomyopathy Screen in Childhood Cancer Survivors
MDedge Internal Medicine
Washington Post Blasts Proliferation of ESAs for Anemia
MDedge Internal Medicine
Long-Term Follow-Up Warranted After Gastric MALT Lymphoma Remission
MDedge Internal Medicine
Anti-TNFs Have Not Raised Lymphoma Risk
MDedge Internal Medicine
Hodgkin's Lymphoma Radiation Linked to Cardiovascular Disease
MDedge Internal Medicine
ASH12: New Proteasome Inhibitor Shines In All-Oral Myeloma Regimen
MDedge Internal Medicine
ASH12: New Myeloma Drug Works Better with Low-Dose Dexamethasone
MDedge Internal Medicine
Pomalidomide: A new option for relapsed myeloma
MDedge Internal Medicine
TOPPS: Limit prophylactic platelets to select groups
MDedge Internal Medicine
MLN9708 regimen effective with reduced neuropathy risk in multiple myeloma
MDedge Internal Medicine